The T-cell lymphoma is a type of non-Hodgkin's lymphoma arising from mature T lymphocytes. T-cell lymphoma usually occurs in the skin, lymph nodes, and blood. Treatment for T-cell lymphoma usually involves chemotherapy, radiation therapy, biologic therapy, or a combination of these treatments.
The Global T-Cell Lymphoma Market Size is estimated to be valued at US$ 7.8 Billion in 2023 and is expected to exhibit a CAGR of 7.7% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The market trend of new product launches is accelerating the growth of the T-cell lymphoma market. Several new product launches with enhanced efficacy and innovative therapies for the treatment of T-cell lymphoma have been announced in recent years. For instance, in October 2022, AlloVir announced the FDA approval of posoleucel, an allogeneic virus-specific T cell (VST) therapy, for the treatment of refractory or relapsed BK virus infection after renal transplant. This marks the first FDA approval of an allogeneic virus-specific T cell therapy. Such new product launches are driving the market growth over the forecast period.
Segment Analysis
The global T-cell Lymphoma market is segmented based on therapy type, application and region. By therapy type, the chemotherapy segment dominates the market due to its low cost and effectiveness in combination with other therapies. The chemotherapy segment is expected to continue its dominance over the forecast period.
Key Takeaways
The global T-cell Lymphoma market is expected to witness high growth over the forecast period of 2024 to 2031.
Regional analysis: North America region holds the major share in T-cell lymphoma market due to growing awareness and availability of advanced treatment options. The region is expected to maintain its dominance due to high healthcare spending and presence of key market players. Asia Pacific region is expected to witness fastest growth during the forecast period owing to growing cases of lymphoma and improving healthcare infrastructure in emerging economies like India and China.
Key players operating in the T-cell Lymphoma market are Bristol-Myers Squibb, Roche, Tesaro, Johnson & Johnson, AbbVie and Seattle Genetics. Bristol-Myers Squibb leads the market with its product Opdivo gaining FDA approval for treating relapsed or refractory T-cell lymphoma. Roche holds significant share with its companion diagnostics and line of therapies targeted towards different stages of T-cell lymphoma.
Get More Insights Here: https://www.newswirestats.com/t-cell-lymphoma-market-size-share-and-growth-forecast-2023-2030/
